Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines

Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients

(2015) Kulthida Rithirangsriroj et al.   GYNECOLOGIC ONCOLOGY

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice

(2014) Mary Lou Affronti et al.   SUPPORTIVE CARE IN CANCER

Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

(2012) K Van Laere et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Nausea still the poor relation in antiemetic therapy? The impact on cancer patients’ quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster

(2012) Carlo Pirri et al.   SUPPORTIVE CARE IN CANCER

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

(2011) Steven Grunberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

A Systematic Review and Meta-Analysis of Intravenous Palonosetron in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Adults

(2011) Z. Likun et al.   ONCOLOGIST

Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva)

(2011) Nissar A. Darmani et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Antiemetic research: future directions

(2010) Ian Olver et al.   SUPPORTIVE CARE IN CANCER

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

(2009) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE